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Enhanced Intravenous Transgene
Expression in Mouse Lung
Using Cyclic-Head Cationic Lipids
packaged therapeutic genes, etc. [8, 9]. Conversely, cat-
ionic lipids, because of their less immunogenic nature,
robust manufacture, ability to deliver very large pieces
of DNA, and ease in handling and preparation tech-
niques, are increasingly becoming the alternative nonvi-
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Lung is one of the most intensely studied sites for2Pharmacology Division
3Electron Microscopy Center pharmaceutical intervention in gene therapy. Cystic fi-
brosis (CF), for example, is a monogenic inherited disor-Indian Institute of Chemical Technology
Hyderabad 500 007 der caused by any of over 1000 mutations in a 230 kb
gene on chromosome 7 encoding a 1480 amino acidIndia
polypeptide, named cystic fibrosis transmembrane con-
ductance regulator (CFTR), that functions as a chloride
ion channel in lung epithelial cell membranes [22].Summary
Lung epithelial cells possessing mutant CFTR genes
are incapable of expressing the functional CFTR pro-Herein, we report enhanced intravenous mouse lung
teins, which in turn leads to pathogenic ion transporttransfection using novel cyclic-head-group analogs of
defects in lungs. Gene expression and appropriateusually open-head cationic transfection lipids. Design
physiological effects have been observed following cat-and synthesis of the new cyclic-head lipid N,N-di-n-
ionic lipid-mediated administration of wild-type CFTRtetradecyl-3,4-dihydroxy-pyrrolidinium chloride (lipid
cDNA into the lung epithelial cells of transgenic CF mice1) and its higher alkyl-chain analogs (lipids 2–4) and
[23, 24] and human CF patients [25]. The focus of manyrelative in vitro and in vivo gene transfer efficacies of
subsequently reported strategies for nonviral systemiccyclic-head lipids 1–4 to their corresponding open-
lung transfection have been centered around the use ofhead analogs [lipid 5, namely N,N-di-n-tetradecyl-
either novel cationic lipids or improved formulations ofN,N-(2-hydroxyethyl)ammonium chloride and its higher
known cationic amphiphiles and DNA [10, 11, 15]. Thealkyl-chain analogs, lipids 6–8] have been described.
latest investigations have demonstrated the enormousIn stark contrast to comparable in vitro transfection
therapeutic potential of using lung as a genetic meta-efficacies of both the cyclic- and open-head lipids,
bolic factory to produce and deliver proteins into thelipids 1–4 with cyclic heads were found to be significantly
circulation for treatment of inherited diseases not di-more efficient (by 5- to 11-fold) in transfecting mouse
rectly associated with lung pathology [26]. Taken to-lung than their corresponding open-head analogs (5–8)
gether, ensuring clinical success of cationic liposomesupon intravenous administration. The cyclic-head lipid
in nonviral gene therapy for treatment of lung-related3 with di-stearyl hydrophobic tail was found to be the
inherited diseases will remain critically dependent onmost promising for future applications.
the use of cationic lipids efficient in delivering genes of
interest into lung cells.Introduction
We have recently reported on design, synthesis, and
high in vitro transfection efficacies of a number of open-Development of efficacious and safe therapeutic gene
head non-glycerol-based cationic lipids containing hy-carriers is the key to clinical success of gene therapy.
drogen bonding hydroxyl head groups for use in nonviralRecombinant viral vectors, although capable of ensuring
gene delivery [19–21, 27]. With a view to probe the rela-high levels of transgene expression into body cells upon
tive transfection efficacies of such open-head hydroxylintravenous administration, suffer from numerous disad-
group containing cationic lipids with their cyclic-headvantages [1–3]. Adenoviral vectors, for example, gener-
counterparts, we designed and synthesized four novelate toxic inflammatory responses [4, 5] and can lead to
cyclic-head cationic lipid analogs (1–4, Figure 1) of ouronset of serious host immune responses against viral
previously reported [27] open-head lipids 5–8 (Figure 1).structural components [6, 7], thereby preventing their
Surprisingly, in sharp contrast to their comparable inreadministration in immunocompetent animals. Addi-
vitro gene transfer properties, in vivo experiments re-tional disadvantages of viral vectors include the follow-
vealed remarkably superior lung transfection efficaciesing: (1) the possibility of random integration into host
of this new generation of cyclic-head cationic lipids (1–4)chromosome, leading to subsequent activation of proto-
compared to their open-head courterparts (5–8). Herein,oncogenes; (2) systemic clearance of viral vectors due to
we delineate the first examples of enhanced intravenouscomplement activation; (3) the possibility of generating
gene expression in mouse lung using cyclic head-groupreplication-competent virus through recombination with
analogs of usually open-head cationic transfection lipids.host genome; (4) the limited insert size of the virally
Results and Discussion
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Chemistry5 This work is dedicated to the memory of the recently expired Sud-
Lipids 1–4 (Figure 1A), the cyclic head-group analogsheer Kumar Yadav, a creative young doctoral student whose dream
was to become a chemical biologist. of our recently developed [27] open-head cationic trans-
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Figure 1. Syntheses and Structures of the
Cyclic- and Open-Head Cationic Lipids
(A) Synthesis of cyclic-head cationic lipids
1–4.
(B) Chemical structures of cationic lipids 5–8.
fection lipids 5–8 (Figure 1B), were designed to decode was found to abolish the transfection efficacies of pres-
ent open- and cyclic-head lipids; data not shown). Boththe relative in vitro and in vivo transfection efficacies of
cationic lipids with open and cyclic polar heads. In terms cyclic- and open-head lipids with di-myristyl (1 and 5)
and di-palmityl (2 and 6) tails were found to be slightlyof bond connectivity patterns, the only difference be-
tween the molecular structures of cyclic-head lipids 1–4 more efficient than lipids with di-stearyl (3 and 7) and
oleyl-stearyl (4 and 8) anchors in transfecting CHO andand their open-head analogs lipids 5–8 is that the hy-
droxyl-group-bearing carbon atoms are covalently HepG2 cells (Figures 2B and 2C). In COS-1 cells, how-
ever, except the lipids with oleyl-stearyl tails (4 and 8),linked to each other in lipids 1–4, and in lipids 5–8 they
are not. Lipids 1–4 were synthesized by dehydrative all the other lipids with both cyclic and open heads were
found to be remarkably transfection efficient (Figure 2A).coupling [28] of the appropriate hydrophobic primary
amine to L()-tartaric acid (Figure 1A) in refluxing xylene Interestingly, at 1:1 lipid:DNA charge ratio, no statisti-
cally significant difference in in vitro transfection proper-so that water formed during the reaction could be sepa-
rated by azeotropic distillation in a Dean-Stark appara- ties were observed for the corresponding open-head
and cyclic-head lipids with same hydrophobic tails, suchtus. The resulting N-n-alkyl-3,4-dihydroxy-2,5-dioxo
pyrrolidine (cyclic imide interemedite I, Figure 1A), upon as lipids 1 and 5, 2 and 6, 3 and 7, etc. (Figures 2A–2C).
In other words, the in vitro transfection efficacies ofreduction with sodium borohydride/iodine, afforded the
corresponding tertiary amine intermediate II (Figure 1A), cyclic- and open-head lipids with the same anchor
lengths were observed to be similar. The in vitro trans-the immediate precursor of the target lipids. Intermedi-
ate II, upon quaternization with hydrophobic alkyl bro- fection efficiencies of many of the present open- and
cyclic-head lipids (particularly those with myristyl andmide in 3:1 (v/v) ethylacetate/acetonitrile followed by
chloride ion exchange on Amberlyst-A26 resin, afforded palmityl chains) were observed to be better than or com-
parable to that of 1, 2-dimyristyloxypropyl-3-dimethyl-the target lipids with cyclic 3,4-dihydroxy-pyrrolidinium
head groups (lipids 1–4, Figure 1A). hydroxyethyl ammonium bromide (DMRIE-C), one of the
most popular commercially available cationic transfec-In Vitro Transfection Studies
Before beginning our in vivo experiments, we first evalu- tion lipids, containing a 2-hydroxyethyl functionality
directly attached to the quaternized nitrogen atom (Fig-ated the in vitro transfection efficacies of both cyclic-
head (1–4) and open-head (5–8) lipids against three cul- ures 2A–2C). Interestingly, both the cyclic- and open-
head lipids 4 and 8, in spite of having membrane-reor-tured mammalian cells, COS-1, CHO, and HepG2,
across the lipid:DNA charge ratios 9:1–0.1:1 (Figures ganizing unsaturated oleyl chains, showed reduced
transfection efficacies in all three cells (Figures 2A–C).2A–2C) using pCMV-SPORT--gal plasmid as the re-
porter gene. Consistent with many other previously re- Taken together, the in vitro transfection efficacies of
both cyclic and open-head lipids were found to beported in vitro studies, both the open-head and cyclic-
head lipids were found to be optimally efficient around equally impressive.
In Vivo Transfection Studieslipid:DNA charge ratio (/) of 1:1 (Figures 2A–2C) using
cholesterol as a colipid at lipid:colipid mole ratio of 1:1 Initial experiments across the lipid:DNA (/) charge
ratios of 2:1–15:1 revealed 4:1 as the optimal in vivo(contrary to many other reports, the usual colipid DOPE
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Figure 2. Relative In Vitro Transfection Profiles of the Cyclic- and Open-Head Cationic Lipids
In vitro transfection efficiencies of lipids 1–8 in COS-1 (A), CHO (B), and HepG2 cells (C) using cholesterol as colipid (at 1:1 molar ratio of
lipid:cholesterol). The transfection efficiencies of the lipids were compared to that of the commercially available reagent DMRIE-C. The
-galactosidase activities in each well were converted to absolute -galactosidase milli-units using a standard curve constructed with pure
(commercial) -galactosidase. All of the lipids were tested on the same day, and the data presented are the average value of two replicate
experiments performed on the same day.
charge ratio for the present lipids (data not shown). sions remaining at maximum values during 8–24 hr post-
injection and then decreasing gradually within 48 hrPreliminary time-course studies showed that onset of
gene expression by the present lipids started at 6 hr (data not shown). Thus, in all subsequent in vivo experi-
ments, transgene expressions were routinely monitoredpost-injection, with the strength of transgene expres-
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lipid:DNA charge ratio of 4:1) were found to be 5- to 11-
fold more efficient in transfecting mouse lung than their
corresponding open-head analogs 5–8 upon intrave-
nous administration (Figure 3A); lipid 3 with di-stearyl
hydrophobic tail being the most promising one for future
applications. Toward further improving efficacies of lipid
3, we tried a reported method of precondensing reporter
gene with protamine sulfate [29, 30]. Unfortunately, such
a strategy did not enhance lung transfection efficiency
of lipid 3 (data not shown). An important observation
deserves to be mentioned at this point: although the
cyclic-head lipid 4 with oleyl-stearyl tail showed signifi-
cant lung transfection efficacy (Figure 3A), half of the
animals injected died within 8 hr post-injection. The pic-
ture became worse with lipid 8 (the open-head analog
of lipid 4): animals died within 2 hr of injecting lipoplexes
of lipid 8 (hence, the open bar data for lipid 8 are missing
in Figure 3A).
Plasma is thought to be one of the major barriers
impeding the efficiencies of intravenous gene delivery
mediated by cationic lipoplexes [31–33]. Investigations
aimed at understanding the interaction of various
plasma components with cationic lipoplexes have just
begun [34]. Identifications of various plasma proteins
capable of binding with lipid:DNA complexes and
thereby destroying their in vivo transfection efficacies
are yet to be deciphered. Thus, the origin of the observed
enhanced lung transfection by cyclic-head lipids (1–4)
compared to their open-head analogs is an open ques-
tion at the present state of investigation. Clearly, preclin-
ical formulation parameters need to be optimized further
before evaluating the clinical potentials of the presently
described cyclic-head cationic lipids for transfecting
Figure 3. Relative In Vivo Transfection Profiles of the Cyclic- and lungs of human CF patients with CFTR gene. For in-
Open-Head Cationic Lipids stance, at the current stage of investigation, the present
(A) Comparative transfection efficiencies of cyclic- and open-head lipids show transient gene expression. Investigations
cationic lipids 1–7 in mouse lung. aimed at accomplishing long-term expression using bet-
(B) Comparative transfection efficiencies of cationic lipids 2, 3, 4, ter lipid formulations and improved expression plasmids
and 7 in heart, spleen, kidney, and liver. Each mouse was intrave-
are currently in progress in our laboratories.nously injected with 25 g of pCMV-Luc complexed to different
cationic lipids at lipid:DNA molar ratio of 4:1. Luciferase activity was
estimated 8 hr post-injection, as described in the text. Data shown
are the mean SD (n  3). Physicochemical Characterizations
of Liposomes and Lipoplexes
Lipoplex Sizes and Zeta Potentials
Measurements of particle sizes using the dynamic laser8 hr post-injection. As observed in many other in vivo
gene transfer studies, remarkable transgene expres- light scattering technique revealed that the sizes of tail-
vein-injected lipoplexes with lipid:DNA charge ratios ofsions were primarily observed in mice lungs (Figure 3A).
Heart was found to be transfected by lipids 2, 3, 4, and 4:1 prepared in 5% glucose solution are sensitive to the
ionic strength of the medium. The sizes increased from7 with about 250- to 300-fold less efficiency than lung
transfection by lipid 3, while expressions in other organs around 100 nm in the absence of any added salt to
150–200 nm (by a factor of 1.5–2.0) in the presence oflike kidney, spleen, and liver progressively diminished
(Figure 3B). 150 mM sodium chloride (Table 1); except in case of
lipid 4, where the corresponding size increase was al-Several contrasting features of open- and cyclic-head
lipids were observed. Although open- and cyclic-head most 3-fold (from 104 nm to 273 nm; Table 1A). This
range is well within the size range of many previouslycationic lipids with myristyl, palmityl, and stearyl tails
showed nearly comparable in vitro transfection efficac- reported in vivo-efficient lipoplexes and is consistent
with high DNA-compacting properties of the presenties (Figures 2A–2C), the efficacies of intravenous lung
transfections were found to increase with increasing tail lipids (given that naked plasmid DNA are usually bigger
than 400 nm). The larger lipoplexes, in the presence ofhydrophobicities of both open- and cyclic-head lipids
(Figure 3A). In stark contrast to comparable in vitro trans- DMEM at 1:1 lipid:DNA charge ratio (with sizes mostly
in the range of 210–250 nm; Table 1A), are more repre-fection efficacies of cyclic- and open-head lipids with
the same hydrocarbon tails (Figures 2A–2C), lipoplexes sentative of the particle sizes involved in the in vitro
experiments. Figure 4 shows the morphological charac-of lipids 1–4 (complexes of lipids and pCMV-luc at
Cyclic-Head Cationic Lipids for Lung Transfection
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Table 1. Size and Surface-Charge Characteristics of the Open- and Cyclic-Head Liposomes and Lipoplexes
A. Hydrodynamic Diameters and Zeta Potentials of Liposomes and Lipoplexes
Hydrodynamic Diameter (nm) Zeta Potential (mV)
Lipids
Lipid:DNA Lipid:DNA Lipid:DNA Lipid:DNA Lipid:DNA Lipid:DNA Lipid:DNA
(1:0) (1:1) (4:1) (4:1) (1:1) (4:1) (4:1)
H2O (DMEM) (5% glucose) (5% glucose  (DMEM) (5% glucose) (5% glucose 
0.15M NaCl) 0.15M NaCl)
1 122  1 213  6 107  2 179  1 36  2 19  3 38  1
5 121  9 218  2 102  2 156  1 37  1 21  3 34  2
2 111  2 227  5 126  2 196  3 49  3 17  4 41  1
6 123  3 221  2 104  2 158  2 36  3 23  3 38  2
3 138  3 239  1 116  2 217  10 37  1 21  3 39  4
7 143  3 252  4 108  4 189  6 33  2 18  3 37  3
4 118  3 172  1 105  4 273  5 33  1 17  2 39  2
8 107  2 245  1 95  1 191  4 38  2 19  3 34  2
B. Hydrodynamic Diameters and Zeta Potentials () of Lipoplexes in the Presence of 90% Mouse Serum
Time (min) Hydrodynamic Diameter (nm) Zeta Potential (mV)
Lipid 3:DNA (4:1) Lipid 7:DNA (4:1) Lipid 3:DNA (4:1) Lipid 7:DNA (4:1)
15 109  4 133  5 8  2 9  1
30 108  2 126  1 10  2 12  1
60 115  1 134  3 12  2 8  1
90 120  2 138  1 11  3 8  1
120 130  5 147  2 11  3 9  2
Average sizes and zeta potentials were measured by a laser light scattering technique using Zetasizer 3000A (Malvern Instruments, United
Kingdom). Values of the hydrodynamic diameters shown are the average of three independent size measurements (calculated by the instrument-
specific cumulant analysis software), where each measurement is the average size of 10 submeasurements. Typical poly-dispersity indices
for liposomes and lipoplexes in the presence of 5% glucose, 5% glucose  0.15M NaCl, and DMEM varied from 0.10 to 0.35, while those in
the presence of mouse serum varied from 0.50 to 0.60. The zeta potential values shown are the average of 10 independent surface potential
measurements.
teristics of the representative lipoplexes 3 and 7 (pre- likely to prevent rapid DNA dissociation from lipoplexes
while in circulation.pared with lipid:DNA charge ratio of 4:1 in deionized
water) obtained by using transmission electron micros- Serum Stabilities
With a view to assess the stability profiles of the presentcopy. Particle sizes obtained from transmission electron
microscopy (Figure 4) were consistent with those ob- lipoplexes under the physiological concentration range
of mouse serum, both size and global surface potentialstained using the dynamic laser light scattering technique
(Table 1A). Interestingly, transmission electron micro- of lipoplexes 3 and 7 (as representative examples) in
the presence of 90% freshly collected mouse serumscopic pictures revealed a closely associated network
of lipoplexes only for those prepared with open-head were determined using a dynamic laser light scattering
technique across a range of incubation times (15–120lipid 7 and not for lipoplexes prepared using the cyclic-
head lipid 3. However, whether or not such networking min) at 37C. The global surface potential measurements
(using a dynamic laser light scattering instrumenttendencies of lipoplex 7 have any correlation with its
poor lung transfection efficacies remains elusive at this equipped with zeta-sizing capacity) for lipoplexes 3 and
7 with 4:1 lipid:DNA charge ratios across this incubationpoint.
Interestingly, global surface potentials (zeta poten- time range revealed the existence of similar negative
surface charges for both in the presence of 90% mousetials, measured by a dynamic light scattering instrument
with zeta-sizing capacity) of almost all of the present serum (8.0 mV to 12.0 mV; Table 1B). These results
are consistent with negatively charged lipoplex particleslipoplexes used in the in vitro experiments were similarly
negative in the presence of DMEM (Table 1A). Surface being involved in the present in vivo lipofection.
Up to 2 hr of incubation in the presence of 90% mousecharges of previously reported efficient cationic li-
poplexes prepared using lipid:DNA charge ratios of 1:1 serum, particle sizes of both the lipoplexes were well
within the usual size ranges for intravenous applications,have been shown to be similarly negative in the presence
of DMEM [35]. This observation supports the notion that with the sizes of the open-head lipoplexes 7 remaining
somewhat higher (126–147 nm) than those of its cyclic-global surface charges are unlikely to play any major role
in modulating in vitro transfection efficacies of cationic head counterpart 3 (108–130 nm; Table 1B). However,
after 2.5 hr incubation in the presence of 90% mouselipids. The surface potentials of all the tail-vein-injected
lipoplexes prepared using 4:1 lipid:DNA charge ratio in serum, the entire mixture within the cuvette transformed
to a gel-like material for both the lipoplexes 3 and 7,5% glucose solutions were observed to be close to20
mV and increased almost by a factor of two in the pres- and no size measurements were possible beyond this
time point. Interestingly, much faster aggregation (withinence of 150 mM sodium chloride (Table 1A). Such a high
positively charged character of the present lipoplexes is 15–90 min) was observed when lipoplexes 3 and 7 were
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Figure 4. Transmission Electron Micrographs of Representative
Lipoplexes
Transmission electron micrographs of lipid:DNA complexes pre-
pared from lipid 3 (A) and lipid 7 (B) and pCMV-Luc at lipid:DNA
charge ratio of 4:1. Bars correspond to 230 nm.(A) and 330 nm (B).
incubated with 10%–70% mouse serum (data not
shown). Such serum-induced rapid aggregation of li-
poplexes have been reported previously by Li et al.,
who demonstrated that the balance between the initial
aggregation rates in the lung capillaries and the rates
Figure 5. Results of the Gel Retardation and DNase-I Sensitivityof the subsequent disintegration of lipidic vectors by
Assays
serum dictates their lung lipofection efficacies [33]. Simi-
(A) Electrophoretic mobilities of the lipid-DNA complexes made from
lar aggregation behaviors of the lipoplexes prepared lipids 1–7 and pCMV-Luc (at lipid:DNA charge ratio of 4:1) through
from lipids 3 and 7 in the presence of varying serum a 1% agarose gel. Free pCMV-Luc was loaded in lane 1, and lanes
concentrations indicate that both the lipoplexes are 2, 3, 4, 5, 6, 7, and 8 were used for loading lipoplexes of cationic
lipids 1, 2, 3, 4, 5, 6, and 7, respectively.likely to be efficiently entrapped in the lung capillaries
(B) DNase I sensitivities of lipid-DNA complexes made from lipids(thereby showing enhanced lung transfection). Thus,
3 and 7 and pCMV-Luc. Free pCMV-Luc and pCMV-Luc treated withbased on the findings of Li et al. [33], the remarkably
DNase I were loaded in lanes 1 and 2. DNase I treated lipoplexes
higher lung transfection efficiency of lipid 3 may possibly of lipid 7 at lipid:DNA charge ratios of 1:1, 4:1, and 9:1 were loaded
be related to its higher subsequent serum-induced disin- in lanes 3, 4, and 5, respectively. Similarly, DNase I-treated li-
tegration rate compared to that for lipid 7. Clearly, de- poplexes of lipid 3 at lipid:DNA charge ratios of 1:1, 4:1, and 9:1
were loaded in lanes 6, 7, and 8.tailed ultrastructural investigations after exposing the
lipoplexes to varying mouse serum concentrations for
different incubation periods and particle distribution
studies using radiolabeled lipoplexes will be needed to using lipoplexes prepared with the optimum in vivo
lipid:DNA charge ratios of 4:1. Results of such gel retar-gain mechanistic insights into the origin of the remark-
ably higher lung transfection properties of lipid 3 than dation assays (Figure 5A) provided convincing support
for the existence of strong electrostatic interactions be-of lipid 7.
Lipid:DNA Binding Interactions and Lipoplex tween lipids 1–7 and plasmid DNA at 4:1 lipid:DNA
charge ratio (lipid 8 was skipped because it was ob-Sensitivities to DNase I
With a view toward gaining insights into the role of served to be toxic, as described below). Such remark-
able lipid:DNA electrostatic binding interactions ob-lipid:DNA electrostatic binding interactions in modulat-
ing the in vivo transfection efficacies of the present lip- served in conventional gel retardation assay (Figure 5A)
were further confirmed by monitoring the sensitivitiesids, conventional gel retardation assays were performed
Cyclic-Head Cationic Lipids for Lung Transfection
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both the cyclic- and open-head lipids showed more than
80% cell viabilities up to lipid:DNA charge ratios of 4:1
(Figure 6). However, the tendency of percent cell viabili-
ties to decrease with increasing lipid:DNA charge ratios
was found to be significantly more pronounced for lipids
with di-myristyl and oleyl-stearyl anchors for both the
open-head and cyclic-head series, compared to their
di-palmityl and di-stearyl counterparts (Figure 6). The
IC50 (inhibitory concentrations of lipids required to inhibit
cell viabilities by 50%) values for lipids 1–8 were directly
estimated (from Figure 6) to be about 75, 285, 340, 60,
70, 	340, 	340, and 40 M, respectively. Thus, the
observed poor transfection efficacies of lipids 4 and 8
(Figure 2) correlate well with their relatively high in vitro
cellular toxicities and low IC50 values. Conversely, the
relatively high IC50 values (
340 M) for lipids 3, 6, and
7 certainly make these lipids worthy of exploiting in
future in vivo applications.
Significance
Designing safe and efficient nonviral transfection vec-
tors for use in gene therapy is an intensely pursued
area of research at the interface of chemistry and biol-
ogy. Cationic lipids, because of their least immuno-
genic nature, are increasingly becoming the nonviral
vectors of choice in effecting in vivo transgene expres-
sion. A vast majority of the existing cationic transfec-
tion lipids contain conformationally unstrained polarFigure 6. Cell Viabilities of the Cyclic- and Open-Head Cationic
Lipids functional groups in their head-group regions. In order
MTT-assay-based cell viabilities of lipids 1–4 (A) and 5–8 (B) in CHO to probe the relative transfection efficacies of usually
cells (details are described in the main text). The data presented open-head cationic lipids and their conformationally
are average values of duplicate experiments (n  2). Results were strained cyclic-head counterparts, we have designed
expressed as percent viability  [A550(treated cells)-background]/ and synthesized four novel cyclic-head analogs of pre-[A550(untreated cells)-background]  100.
viously reported open-head cationic transfection lip-
ids with tails of increasing hydrophobicity and evalu-
of the representative lipoplexes 3 and 7 upon treatment ated their transfection efficiencies (both in vitro and
with DNase I at lipid:DNA charge ratios of 9:1, 4:1, and in vivo). Herein, we demonstrate that in vivo lung trans-
1:1. After the free DNA digestion by DNase I, the total fection efficacies of cationic lipids can be significantly
DNA (both the digested and inaccessible DNA) were (5- to 11-fold) enhanced through design and synthesis
separated from lipid (by extracting with organic sol- of appropriate conformationally strained cyclic-head
vents) and loaded on a 1% agarose gel. Consistent with analogs of their usually open-head structures. Similar
observations in the gel retardation assays (Figure 5A), aggregation behavior of lipoplexes 3 and 7 in the pres-
DNase I digestion assays (Figure 5B) did not reveal the ence of varying serum concentrations indirectly sup-
existence of any significant electrostatic interaction dif- ports the notion that both of the lipoplexes are effi-
ference between lipoplexes prepared from the represen- ciently entrapped in the lung capillaries. The superior
tative cyclic-head and open-head cationic lipids 3 and lung transfection efficiency of the cyclic-head lipid
7. Taken together, the results summarized in Figure 5 might possibly be related to its faster subsequent se-
support the notion that electrostatic lipid:DNA interac- rum-induced distintegration rate compared to that for
tions are unlikely to be significantly different for both the lipid 7. The present findings are likely to provide impe-
presently described open-head and cyclic-head lipids. tus for future structure-activity investigations aimed
Cell Viabilities at improving in vivo transfection properties of usually
To assess the relative cytotoxicities and IC50 concentra- open-head cationic transfection lipids through design-
tions of the present cationic lipids, cell viabilities of li- ing their appropriate cyclic-head analogs.
poplexes 1–8 were measured using MTT-based cell via-
bility assays in representative CHO cells across a wide Experimental Procedures
range of lipid:DNA charge ratios of 1:1–75:1. Interest-
General Procedures and Reagentsingly, cell viability profiles of the cyclic-head lipoplexes
The FABMS analyses were performed on a Micromass AUTO-1–4 across this entire range of lipid:DNA charge ratios
SPEC-M mass spectrometer (Manchester, United Kingdom) with(Figure 6A) were found to be remarkably similar to those
OPUS V3, 1X data system. Data were acquired by liquid secondary
for the corresponding open-head lipoplexes 5–8 (Figure ion mass spectrometry (LSIMS) using meta-nitrobenzyl alcohol as
6B). Except the lipids containing oleyl and stearyl chains the matrix. 1H NMR spectra were recorded on a Varian FT 200 MHz.
1-bromotetradecane, 1-bromohexadecane, 1-bromooctadecane,(4 and 8), all of the remaining lipoplexes prepared from
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n-tetradecylamine, n-hexadecylamine, and n-octadecylamine were process was repeated three times. The residue obtained was treated
with a solution of potassium hydroxide (1 g) in methanol (25 ml),procured from Lancaster (Morecambe, United Kingdom). Column
chromatography was performed with silica gel (Acme Synthetic and solid anhydrous potassium carbonate (35 g) was added. The
solution was filtered and the solvent from filtrate was evaporatedChemicals, India, 60–120 mesh). DMRIE-C reagent was purchased
from Gibco BRL, Life Technologies. Cell culture media, fetal bovine to dryness. Column chromatographic purification of the resulting
residue using silica gel (60–120 mesh size) and 4% (v/v) methanol-serum, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT), polyethylene glycol 8000, o-nitrophenyl-D-galactopyrano- chloroform as eluent afforded 3.75 g (58.5%) of the title compound
as a white solid (Rf  0.35, 10% methanol/ chloroform, v/v).side, and cholesterol were purchased from Sigma, St. Louis, MO.
NP-40, antibiotics, and agarose were purchased from Hi-Media, N-n-tetradecyl-3,4-dihydroxypyrrolidine (II, R1  n-C14H29, Figure
1A). 1H NMR (200 MHz, CDCl3): /ppm  0.90 [t, 3H, CH3-(CH2) 13-],India. Unless otherwise stated, all other reagents purchased from
local commercial suppliers were of analytical grades and were used 1.10-1.35 [bs, 22H, -(CH2) 11-], 1.40-1.50 [m, 2H, N(-CH2-CH2-)], 2.30-
2.55 [m, 4H, N-CH2-(CH2)11, HaHbC(CHOH)-NR1-C(CHOH)HaHb]; 2.85-without further purification.
3.00 [m, 2H, HaHbC(CHOH)-NR1-(CHOH)CHaHb], 4.00-4.15 [bs, 2H,
-CH(OH)-CH(OH)-], 4.80-5.00 [bs, 2H, OH]. FABMS (LSIMS): m/z:Synthesis of Lipids 1–4
300 [M1] for C18H37O2N.Lipids 1–4 were synthesized following strategies depicted schemati-
N-n-hexadecyl-3,4-dihydroxypyrrolidine (II, R1  n-C16H33, Figurecally in Figure 1A. As a representative experimental detail, synthesis
1A). 1H NMR (200 MHz, CDCl3): /ppm  0.90 [t, 3H, CH3- (CH2)15-],of only lipid 1 is outlined below. Lipids 2–4 were synthesized follow-
1.15-1.35 [bs, 26H, -(CH2)13-], 1.40-1.50 [m, 2H, N(-CH2-CH2-)], 2.30-ing the same protocol as described for lipid 1. 1H NMR and mass
2.50 [m, 4H, N-CH2-(CH2)14, HaHbC(CHOH)-NR1-C(CHOH)HaHb], 2.85-spectral data of all of the purified new cationic lipids 1–4 with cyclic
3.00[m, 2H, HaHbC(CHOH)-NR1-(CHOH)CHaHb], 4.00-4.15 [bs, 2H,head groups are provided below the synthetic details for lipid 1.
-CH(OH)-CH(OH)-], 3.4 [s, 2H, OH].The cyclic tertiary amine intermediate II (Figure 1A) was prepared
N-n-octadecyl-3,4-dihydroxypyrrolidine (II, R1  n-C18H37, Figurefrom L()-tartaric acid essentially following a procedure described
1A). 1H NMR (200 MHz, CDCl3): /ppm  0.90 [t, 3H, CH3-(CH2)17-],previously [28]. The open-head cationic lipids 5–8 (Figure 1B) were
1.10-1.35 [bs, 30H, -(CH2)15-], 1.40-1.50 [m, 2H, N(-CH2-CH2-)], 2.30-synthesized as described previously [27].
2.55 [m, 4H, N-CH2-(CH2)16, HaHbC(CHOH)-NR1-C(CHOH)HaHb], 2.85-
3.00 [m, 2H, HaHbC(CHOH)-NR1-(CHOH)CHaHb]; 4.0-4.15 [bs, 2H,Synthesis of Lipid 1
-CH(OH)-CH(OH)-], 1.80-2.20 [bs, 2H, OH]. FABMS (LSIMS): m/z:Step A
356 [M1] for C22H45O2N.Synthesis of N-tetradecyl-3,4-di-hydroxy-2,5-dioxo-pyrrolidine (I,
Step CR1  n-C14H29, Figure 1A). In a 500 ml round-bottomed flask, n-tetra-
Synthesis of N,N-di-n-tetradecyl-3,4-dihydroxy pyrrolidinium chlo-decylamine (21.3 g, 100 mmol) was refluxed in xylene (200 ml) with
ride (R1  R2  n-C14H29, Figure 1A). N-n-tetradecyl-3,4-dihydroxy-L()-tartaric acid (15 g, 100 mmol) for 3 hr. The water formed in the
pyrrolidine II, (1g, 3.3 mmole, prepared in Step B above) andreaction was removed azeotropically using a Dean-Stark apparatus.
n-tetradecylbromide (3 ml, 10.0 mmol) were dissolved in ethylacet-After completion of water removal in the Dean-Stark, the reaction
ate:acetonitrile solvent mixture (3:1, 40 ml) in a 100 ml round-bot-mixture was cooled, and the crystalline product was filtered off and
tomed flask and refluxed for 96 hr. The solvent was evaporated onwashed with hexane (100 ml). The crude product upon recrystalliza-
a rotary evaporator, and column chromatographic purification oftion from hexane-methanol (4:1, 100 ml) afforded 15.2 g (47% yield)
the residue (using 60–120 mesh silica gel and 4% methanol-chloro-of the pure N-tetradecyl-3,4-dihydroxy-2,5-dioxo pyrrolidine as a
form, v/v, as eluent) followed by chloride ion exchange in Amberlystwhite solid (Rf  0.5, 10% methanol/ chloroform, v/v).
A-26 using methanol as the eluent afforded the title compound asN-n-tetradecyl-3,4-dihydroxy-2,5-dioxo pyrrolidine (I, R1  n-C14
a white solid (1.17 g, 66%, Rf  0.3, 10% methanol/chloroform, v/v).H29, Figure 1A). 1H NMR (200 MHz, CDCl3  DMSO-d6): /ppm 
N,N-di-n-tetradecyl-3,4-dihydroxy pyrrolidinium chloride, Lipid 10.90 [t, 3H, CH3-(CH2)13-], 1.20-1.40 [bs, 22H, -(CH2)11-], 1.50-1.85 [m,
(R1  R2  n-C14H29, Figure 1A). 1H NMR (200 MHz, CDCl3): /ppm 2H, N(-CH2-CH2-)], 3.30-3.50 [t, 2H, N-CH2-(CH2) 12-], 4.30-4.40 [bs,
0.90 [t, 6H, CH3- (CH2)13-], 1.20-1.40 [bs, 44H, -(CH2)11-], 1.50-1.802H, -CH(OH)-CH(OH)-], 6.00-6.20 [bs, 2H, -OH].
[m, 4H, N(-CH2-CH2-)2 ], 3.40-3.50 [t, 4H, N (CH2-(CH2)12], 3.70-4.00 [m,N-n-hexadecyl-3,4-dihydroxy-2,5-dioxo pyrrolidine (I, R1  n-C16
4H, H2C(CHOH)-NR1R2-(CHOH)CH2], 4.50-4.60 [bs, 2H, -CH(OH)-H33, Figure 1A). 1H NMR (200 MHz, CDCl3  DMSO-d6): /ppm 
CH(OH)-], 6.00-6.10 [bs, 2H, -OH]. FABMS (LSIMS): m/z: 496 [M]0.90 [t, 3H, CH3-(CH2)15-], 1.10-1.30 [bs, 26H, -(CH2)13-], 1.40-1.60 [m,
for C32H66O2N.2H, N(-CH2-CH2-)], 3.30-3.40 [t, 2H, N-CH2-(CH2) 14-], 4.20-4.30 [bs,
N,N-di-n-hexadecyl-3,4-dihydroxypyrrolidinium chloride, Lipid 22H, -CH(OH)-CH(OH)-], 6.00-6.20 [bs, 2H, -OH].
(R1  R2  n-C16H33, Figure 1A). 1H NMR (200 MHz, CDCl3): /ppm N-n-octadecyl-3,4-dihydroxy-2,5-dioxo pyrrolidine (I, R1  n-C18
0.90 [t, 6H, CH3- (CH2)15-], 1.20-1.40 [bs, 52H, -(CH2)13-], 1.60-1.90H37, Figure 1A). 1H NMR (200 MHz, CDCl3  DMSO-d6): /ppm 
[m, 4H, N(-CH2-CH2-)2], 3.30-3.50 [bs, 4H, N CH2-(CH2)14-], 3.70-4.000.90 [t, 3H, CH3-(CH2)17-], 1.10-1.40 [bs, 30H, -(CH2)15-], 1.50-1.65 [m,
[m, 4H, H2C(CHOH)-NR1R2-(CHOH)CH2], 4.50-4.60 [bs, 2H, -CH(OH)-2H, N(-CH2-CH2-)], 3.30-3.50 [t, 2H, N-CH2-(CH2) 16-], 4.30-4.40 [bs,
CH(OH)-], 6.00-6.20 [bs, 2H, -OH]. FABMS (LSIMS): m/z: 552 [M]2H, -CH(OH)-CH(OH)-], 6.00-6.20 [bs, 2H, -OH].
for C36H74O2N.Step B
N,N-di-n-octadecyl-3,4-dihydroxy pyrrolidinium chloride, Lipid 3Synthesis of N-n-tetradecyl-3,4-dihydroxypyrrolidine (II, R1  n-C14
(R1  R2  n-C18H37, Figure 1A). 1H NMR (200 MHz, CDCl3): /ppm H29, Figure 1A). N-n-tetradecyl-3,4-dihydroxy-2,5-dioxo pyrrolidine,
0.90 [t, 6H, CH3- (CH2) 17-], 1.20-1.40 [bs, 60H, -(CH2)15-], 1.50-1.80I (7.0 g, 21 mmoles, prepared in Step A above) dissolved in dry
[m, 4H, N(-CH2-CH2-)2], 3.40-3.50 [t, 4H, N-CH2-(CH2)16-], 3.70-4.00tetrahydrofuran (50 ml) was added to a stirred slurry of NaBH4 (4.40 g,
[m, 4H, H2C(CHOH)-NR1R2-(CHOH)CH2], 4.50-4.60 [bs, -CH(OH)-116 mmoles) in tetrahydrofuran (50 ml) in a 500 ml two-necked
CH(OH)-], 6.00-6.10 [bs, 2H, -OH]. FABMS (LSIMS): m/z: 608 [M]round-bottomed flask equipped with a reflux condenser and a drop-
for C40H82O2N.ping funnel. Iodine (13.04 g, 51 mmoles) dissolved in tetrahydrofuran
N-n-octadecyl-N-oleyl-3,4-dihydroxy pyrrolidinium chloride, Lipid(100 ml) was added from the dropping funnel under N2 atmosphere
4 (R1  n-C18H37, R2 oleyl, Figure 1A). 1H NMR (200 MHz, CDCl3):at 0C for a period of 2.5 hr. The mixture was refluxed for 6 hr,
/ppm  0.90 [t, 6H, CH3-(CH2)17-], 1.20-1.45 [bs, 54H, -(CH2)27-],cooled to 0C, and the excess sodium borohydride was carefully
1.60-1.80 [m, 4H, N(-CH2-CH2-)2], 1.90-2.20[m, 4H, -CH2-CHCH-decomposed with 3N HCl (10 ml). After the evolution of gas ceased,
CH2-], 3.35-3.50 [bs, 4H, N-CH2-(CH2)16-], 3.70-4.00 [m, 4H,the mixture was neutralized with 3N NaOH (15 ml), the organic layer
H2C(CHOH)-NR1R2-(CHOH)CH2], 4.60 [bs, 2H, -CH(OH)-CH(OH)-],was separated, and the aqueous layer was extracted with ether (150
5.30 [t, 2H, -CH2-CHCH-CH2-], 6.00-6.20 [bs, 2H, -OH]. FABMSml). The combined organic extract was washed with brine (100 ml),
(LSIMS): m/z: 607 [M1] for C40H80O2N.water (2 100 ml), and dried over anhydrous Na2SO4. After evaporat-
ing the solvent on a rotary evaporator, the crude product was dis-
solved in 30 ml methanol, and 6 ml 12N HCl was added to it. After Animals and Cells
Male Balb/c mice were obtained from National Institute of Nutrition,the exothermic reaction, methanol was distilled off and the mixture
was diluted with methanol (50 ml), which was removed again. This Hyderabad, India, and all of the in vivo experiments were performed
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in accordance with the Institutional Bio-Safety and Ethical Commit- was estimated by adding 50 l of 2X-substrate solution (1.33 mg/
ml o-nitrophenyl-D-galactopyranoside, 0.2 M sodium phosphatetee guidelines using an approved animal protocol. COS-1 (SV 40
transformed African green monkey kidney cells), CHO (Chinese ham- [pH 7.3], and 2 mM magnesium chloride) to the lysate in a 96-well
plate. Absorbance of the product ortho-nitrophenol at 405 nm wasster ovary), and HepG2 (Human hepatocarcinoma) cell lines were
procured from the National Centre for Cell Sciences (NCCS), Pune, converted to -galactosidase units by using a calibration curve con-
structed using pure commercial -galactosidase enzyme. The trans-India. Cells were cultured at 37C in Dulbecco’s modified Eagle’s
medium (DMEM) with 10% Fetal Bovine serum, 50 g/ml penicillin, fection values reported are the average values from two replicate
experiments performed in the same plate on the same day. Each50 g/ml streptomycin, and 20 g/ml kanamycin in a humidified
atmosphere containing 5% CO2. transfection experiment was performed three times on three differ-
ent days. The day-to-day variation in transfection efficiency was
mostly within 2- to 3-fold and was dependent on the cell densityPlasmids
and condition of the cells.pCMV-Luc and pCMV-SPORT--gal plasmids were generous gifts
from Dr. Leaf Huang (Department of Pharmacogenetics, University
of Pittsburgh, School of Medicine, Pittsburgh, PA) and Dr. Nalam Zeta Potential and Size Measurments
Madhusudhana Rao (Centre for Cellular and Molecular Biology, Hy- The sizes and the global surface charges (zeta potentials) of li-
derabad, India), respectively. These plasmids were amplified in the poplexes were measured by photon correlation spectroscopy and
DH5 strain of Escherichia coli, isolated by alkaline lysis procedure, electrophoretic mobility with a Zetasizer 3000HSA (Malvern Instru-
and finally purified by PEG-8000 precipitation as described pre- ments, United Kingdom). The system was calibrated by using the
viously [36]. The purity of plasmid was checked by A260/A280 ratio 199  6 nm Nanosphere Size Standard (Duke Scientific Corp., Palo
(around 1.9) and 1% agarose gel electrophoresis. Alto, CA) and DTS 0050 standard from Malvern.
Preparation of Liposomes and Lipid-DNA Complexes DNA Binding Assay
Cationic lipids and cholesterol (in 1:1 molar ratio) in chloroform were The DNA binding ability of cationic lipids 1–7 was assessed by their
taken in 30 ml glass culture tubes, dried under a stream of nitrogen gel retardation assay on a 1% agarose gel. 0.30 g of pCMV-Luc
gas, and vacuum dessicated for a minimum of 6 hr to remove any was complexed with the cationic lipids (at a cationic lipid:DNA molar
residual organic solvent. The dried lipid film was hydrated in sterile ratio of 4:1) in a total volume of 16 l in HEPES buffer (pH 7.40) and
deionized water (for in vitro) or 5% w/v glucose water (for in vivo) incubated at room temperature for 20–25 min. Three micoliters of
in a total volume of 5 ml at cationic lipid concentration of 1 mM and 6X loading buffer (0.25% bromo phenol blue, 40% sucrose) was
5 mM, respectively, for a minimum of 12 hr. Liposomes were vor- added to it, and 6.3 l of the resultant solution was loaded on each
texed for 2–3 min to remove any adhering lipid film and sonicated well. The samples were electrophoresed at 80 V for approximately
in a bath sonicator (ULTRAsonik 28X) for 2–3 min at room tempera- 2 hr, and the DNA bands were visualized by staining overnight with
ture to produce multilamellar vesicles (MLV). MLVs were then soni- ethidium bromide solution.
cated with a Ti-probe (using a Branson 450 sonifier at 100% duty
cycle and 25 W output power) in an ice bath for 1–2 min to produce
DNase 1 Sensitivity Assaysmall unilamellar vesicles (SUVs) as indicated by the formation of
Briefly, in a typical assay 1.5 nmol of DNA (500 ng) was complexeda clear translucent solution. For preparation of lipid-DNA complexes
with lipid using the indicated lipid:DNA charge ratios (Figure 5B),(in vivo), pDNA (25 g) and cationic liposomes (using appropriate
and the mixture was incubated at room temperature for 30 min onvolumes of stock liposomes and pDNA for preparing lipoplexes with
a rotary shaker. Subsequently, the complexes were treated withthe lipid:DNA molar ratio of 4:1) were diluted to 150 l each with
DNase I (at a final concentration of 5 ng/1.5 nmol of pDNA) in the5% w/v glucose solution in sterile 1.5 ml microfuge tubes separately.
presence of 20 mM MgCl2. The volume was made up to 50 l withThe pDNA solution was added to the liposomes, mixed properly by
10 mM HEPES buffer (pH 7.4) and incubated for 20 min at 37C.pipetting up and down a few times, and kept at room temperature
The reactions were then halted by adding EDTA (to a final concentra-for 15–30 min before use. The final concentration of pDNA and
tion of 20 mM) and incubated at 60C for 10 min in a water bath.cationic lipids (1–8) used for intravenous injection were 83.3 g/ml
The aqueous layer was washed with 50 l of phenol:chloroformand 536–650 g/ml, respectively.
mixture (1:1, v/v) and centrifuged at 10,000 rpm at 4C for 5 min.
The aqueous supernatant was separated, loaded (20 l) on a 1%In Vivo Delivery and Gene Expression
agarose gel, and electrophoresed at 90 V for 3 hr. The bands wereEach 6-week-old male Balb/c mouse (20 g) was injected in the
visualized with ethidium bromide staining.tail vein with 300 l of the liposome-DNA complexes using a 26.5
gauge syringe needle. Mice were sacrificed 8 hr post-injection, and
Toxicity Assayorgans were harvested and washed in cold saline. Four hundred
Cytotoxicities of lipids 1–8 were assessed by the 3-(4,5-dimethylthi-microliters of lysis buffer (0.1 M Tris-HCl, 2 mM EDTA, and 0.2%
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assayTriton X-100, pH 7.8) was added to each organ and homogenized
as described earlier [38]. The cytotoxicity assay was performedusing a mechanical homogenizer. The homogenates were centri-
in 96-well plates using the same conditions as described for thefuged at 14,000 rpm for 10 min at 4C, and 2–5 l of the supernatant
transfection experiments. Briefly, after 3 hr of lipid:DNA complexwas assayed using the Promega Luciferase assay kit (Madison, WI)
addition, DMEM containing 20% FBS (100 l) and MTT (10 l, 5in a Microplate Luminometer (Berthold, Germany). Protein concen-
mg/ml in PBS buffer) was added to each well. After 3–4 hr, mediumtration of each tissue extract was determined by the modified Lowry
was removed, 100 l of DMSO:Methanol (1:1, v/v) was added toprocedure [37], and the luciferase activity in each organ was ex-
each well and shaken in a rotary shaker for 20–25 min. Results arepressed as the relative light unit (RLU) per mg of extracted protein.
expressed as percent viability  [A550(treated cells)-background/
A550(untreated cells)-background]  100.In Vitro Transfection Studies
Cells were seeded at a density of 15,000 (for COS-1) and 20,000
(for CHO and HepG2) per well in a 96-well plate 18–24 hr before Transmission Electron Microscopy
Electron microscopy was performed on a FEI Tecnai 12 TEM appara-transfection. 0.30 g of pDNA was complexed with varying amounts
of lipids (to give / ratios of 0.1:1, 0.3:1, 1:1, 3:1, and 9:1) in tus operated at 100 KV. Lipoplex samples were transferred onto an
ultrathin-carbon-coated copper grid by placing the grid on top of aplain DMEM (total volume made up to 100 l) for 20–30 min. The
complexes were then added to the cells. After 3 hr of incubation, 10 l drop of the sample for 1 min. After wicking away the excess
fluid from one side, the grid was placed on a 100 l water drop for100 l of DMEM with 20% FBS was added to the cells. The medium
was changed to complete medium containing 10% FBS after 24 hr, 30 s wash. The excess fluid was removed and the grid was placed
for 1 min on a 20 l drop of freshly filtered uranyl acetate (1.33%).and the reporter gene activity was estimated after 48 hr. Cells were
washed with PBS (100 l) and lysed in 50 l lysis buffer (0.25 M Once again, the excess fluid was wicked away and the grid was air
dried.Tris-HCl [pH 8.0], 0.5% NP40). The -galactosidase activity per well
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